Breaking Down COVID-19

EDITOR’S NOTE: Julia Brodt is a microbiologist with 12 years of medical research experience and 22 years teaching in higher education who, along with her husband, John K. Hall, MD, is a member of the RACmonitor Editorial Board and a recurring special guest on Monitor Mondays. This is the first segment in her new series taking a deep dive into the known clinical and medical facts of COVID-19.

The virus SARS-CoV-2, known for causing COVID-19, is a novel coronavirus that took the U.S by surprise. The first case entered the country in mid-January 2020, and just seven months later, current COVID deaths are currently nearing 170,000.

Treatments act to support patients who test positive for the disease, as there is no vaccine. A recent study by investigators at Harvard, MIT, the Ragon Institute of MGH, and the University of Washington School of Medicine found that five immune markers in serum were able to distinguish which SARS-CoV-2-positive patients were likely to convalesce, and which patients would not survive. As patients exhibit a range of symptoms, this information could be useful for determining an earlier prognosis to indicate supportive treatments or reveal possible targets for vaccine production.

The SARS-CoV-2 virus is comprised of several key components, including its genetic material, a single positive strand of ribonucleic acid (RNA) linked with nucleoproteins (N), a covering of protein and membrane (M), and spikes (S) that protrude away from anchors in the spherical envelope. A segment on Monitor Mondays airing on Aug. 10 presented background information about the structure and function of human antibodies. The viral S proteins permit virus attachment to host cells via a cell membrane protein, angiotensin-converting enzyme 2, or ACE2, which is found on many cell types in humans, namely those lining body passages like digestive and respiratory tracts. Once the virus attaches itself, it fuses with the host cell membrane, the RNA enters the cell, and it hijacks the cell machinery and makes copies of itself to infect other host cells.

Galit Alter, co-author of the group study “COVID-19 Patients Exhibit Early Antibody Signatures Predictive of Death or Recovery,” stated that a goal of the project was to examine the immune profile of positive patients, after which “we can begin to truly understand how the immune system responds to COVID-19, then use that knowledge to prevent the worst outcomes of this disease.”

It is thought that coronaviruses replicate in human hosts, even though some patients may remain asymptomatic, while others sicken and die. To determine a disease trajectory, more understanding of antibody production is needed. A test group of 22 patients hospitalized for COVID-19 provided samples for testing. Using 60 assays, detailed immune profiles were created. Of these 22 patients, 12 recovered, while 10 did not survive. It had been shown that viruses make more N protein than S protein within the host, but interestingly, those who survived had produced a stronger immune response to the S protein, whereas those who died generated more antibodies to the N protein. Furthermore, the antibodies could be characterized as IgM and IgA1, produced in the S protein survivors, and IgM and IgA2, along with complement (serum proteins involved in inflammation) generated against the N protein in non-survivors. This data was confirmed in a follow-up of 40 patients, 20 survivors and 20 who died.

Based upon their antibody status, these COVID-19 patient profiles identified who would make it and who would not. This information presents an approach to determine patients at risk for severe sequelae and those in diminished danger for death. This data opens doors to potential treatments.

Facebook
Twitter
LinkedIn

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

2026 IPPS Masterclass 3: Master MS-DRG Shifts and NTAPs

2026 IPPS Masterclass Day 3: MS-DRG Shifts and NTAPs

This third session in our 2026 IPPS Masterclass will feature a review of FY26 changes to the MS-DRG methodology and new technology add-on payments (NTAPs), presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 14, 2025
2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

This second session in our 2026 IPPS Masterclass will feature a review the FY26 changes to ICD-10-PCS codes. This information will be presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 13, 2025
2026 IPPS Masterclass 1: Master ICD-10-CM Changes

2026 IPPS Masterclass Day 1: Master ICD-10-CM Changes

This first session in our 2026 IPPS Masterclass will feature an in-depth explanation of FY26 changes to ICD-10-CM codes and guidelines, CCs/MCCs, and revisions to the MCE, presented by presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 12, 2025

Trending News

Featured Webcasts

The Two-Midnight Rule: New Challenges, Proven Strategies

The Two-Midnight Rule: New Challenges, Proven Strategies

RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.

June 19, 2025
Open Door Forum Webcast Series

Open Door Forum Webcast Series

Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.

June 11, 2025
Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025.  Register today and be a part of the conversation!

July 16, 2025

Trending News

Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more

Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24